「小普日報(bào)」2023年5月30日熱點(diǎn)速遞

關(guān)鍵詞
抗體偶聯(lián)藥物 ADC 抗體 抗原 紅細(xì)胞 免疫檢查點(diǎn)抑制劑 伊努西單抗?諾如病毒 疫苗
?
#今日行業(yè)熱點(diǎn)#
①The Lancet:Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
臨床試驗(yàn):新型HER2靶向抗體偶聯(lián)藥物(ADC)Trastuzumab Deruxtecan((T-DXd))在HER2陽性轉(zhuǎn)移性乳腺癌患者中的一項(xiàng)隨機(jī)、開放標(biāo)簽、多中心、Ⅲ期試驗(yàn)
DOI: 10.1016/S0140-6736(23)00725-0
②Journal of Clinical Oncology:Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
綜述:抗體-藥物偶聯(lián)物(ADC)在肺癌領(lǐng)域中的研究進(jìn)展和實(shí)施策略
DOI: 10.1200/JCO.23.00013
③Science Translational Medicine:Antibody-cytokine fusion breathes new life into glioblastoma therapy
抗體-細(xì)胞因子融合通過增強(qiáng)抗腫瘤免疫,在小鼠和復(fù)發(fā)性膠質(zhì)母細(xì)胞瘤患者中誘導(dǎo)腫瘤消退
DOI: 10.1126/scitranslmed.adh7674
④Blood:Cytosolic antigens prime RBC alloantibodies
細(xì)胞溶質(zhì)抗原可能導(dǎo)致對其他紅細(xì)胞表面同種抗原的高反應(yīng)性
DOI: 10.1182/blood.2022019596
⑤Chemical Communications:Targeted delivery of alcohol-containing payloads with antibody-drug conjugates
用抗體-藥物偶聯(lián)物(ADC)靶向遞送含酒精的有效載荷
DOI: 10.1039/d3cc01596c
⑥Cancer Letters:Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions
綜述:免疫檢查點(diǎn)抑制劑(ICI)在癌癥領(lǐng)域的耐藥機(jī)制研究中需要解決的挑戰(zhàn)和機(jī)遇
DOI: 10.1016/j.canlet.2023.216182
⑦新一代高選擇性布魯頓氏酪氨酸激酶 (BTK) 抑制劑阿可替尼(CALQUENCE?)在中國上市,用于成人套細(xì)胞淋巴瘤(MCL)
⑧伊努西單抗(PCSK9)用于原發(fā)性高膽固醇血癥和混合型高脂血癥患者的Ⅲ臨床數(shù)據(jù)公布,已提交上市申請
⑨國產(chǎn)重組諾如病毒雙價(jià)疫苗啟動(dòng)Ⅲ期臨床試驗(yàn),針對由GI.1型和GII.4型諾如病毒感染引起的中/重度急性胃腸炎
⑩抗CTLA-4全人源單克隆重鏈抗體(HCAb)聯(lián)合抗PD-1抗體特瑞普利單抗用于肝細(xì)胞癌(HCC)患者的Ib期臨床試驗(yàn)獲得積極數(shù)據(jù)
科學(xué)探索的世界充滿挑戰(zhàn),AtaGenix致敬每一位拓荒者,更致力于成為您信賴的合作伙伴!